CompletedNot Applicable

Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion

United States53 participantsStarted 2023-08-01

Plain-language summary

The objective of this study is to evaluate the performance of Induce Biologics NMP™ when used to promote interbody fusion for degenerative disease of the lumbar spine.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Have clinical or radiological evidence of degenerative disc disease of the lumbar spine.
✓. Have been treated with Induce Biologics NMP™ during a lumbar spinal fusion procedure.
✓. Be at least 18 years of age.
✓. Have current contact information.
✓. Be willing and able to provide written Informed Consent for the prospective part of study participation.
✓. Be willing and able to undergo a CT-scan and X-rays.
✓. Be willing and able to complete patient centered outcome questionnaires.

Exclusion criteria

✕. Currently imprisoned.
✕. Currently experiencing major mental illness (psychosis, schizophrenia, major affective disorder) which in the opinion of the investigator may indicate that the symptoms are psychological rather than of physical origin.
✕. X-rays or CT-scan are contraindicated.
✕. Any previous lumbar fusion or arthroplasty surgery at the index level(s)

What they're measuring

Radiographic fusion rate

Timeframe: 12-months post-surgery

Trial details

NCT IDNCT05972616

SponsorInduce Biologics USA Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-02-21

View on ClinicalTrials.gov More Degenerative Disc Disease trials